# Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity

> **NCT05098470** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **University of Alabama at Birmingham** · enrollment: 100 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Metformin
- **DRUG:** Insulin Glargine
- **DRUG:** Dorzagliatin

## Key facts

- **NCT ID:** NCT05098470
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-07
- **Primary completion:** 2025-07-29
- **Final completion:** 2026-07-29
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-07-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05098470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05098470, "Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05098470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*